© Copyright Acquisition International 2025 - All Rights Reserved.

Article Image - Agreement to Acquire Boehringer
Posted 7th October 2016

Agreement to Acquire Boehringer

Elanco Animal Health Enters Agreement to Acquire Boehringer Ingelheim Vetmedica's U.S. Feline, Canine and Rabies Vaccines Portfolio

Mouse Scroll AnimationScroll to keep reading

Let us help promote your business to a wider following.

Agreement to Acquire Boehringer
Image

Eight new product lines and a fully integrated manufacturing and R&D site to transfer to Elanco, adding to its growing companion animal business; subject to FTC approval and closing of BI/Sanofi asset swap

Today Elanco U.S., Inc., a subsidiary of Eli Lilly and Company, announced an agreement to acquire Boehringer Ingelheim Vetmedica, Inc.’s (BIVI) U.S. feline, canine and rabies vaccines portfolio – as well as a fully integrated manufacturing and R&D site – for $885 million, including the estimated cost of acquired inventory. The deal will diversify Elanco’s U.S. companion animal portfolio by complementing its offerings for dogs and cats.

Joining Elanco’s U.S. portfolio – which currently includes parasiticides, pain and dermatology medicines – will be routinely administered vaccines for bordetella, Lyme disease, rabies and parvovirus, among others. Also included in the agreement are several pipeline assets.

The Fort Dodge, Iowa-based facility brings capacity to manufacture the acquired products as well as R&D and testing capabilities, including an on-site veterinary research center and lab space.

“We understand the unique bond that owners share with pets and are committed to helping those pets live longer, healthier lives,” said Jeff Simmons, president, Elanco Animal Health. “With a growing portfolio addressing both prevention and treatment of disease, Elanco can partner with veterinarians and pet caregivers to do just that.”

The acquisition is anticipated to close by early 2017, subject to approval by the Federal Trade Commission and also subject to antitrust approval and closing of Boehringer Ingelheim’s asset swap transaction with Sanofi.

The sale of BIVI’s U.S. pet vaccines business and Fort Dodge manufacturing site is a required step toward the acquisition of Merial by Boehringer Ingelheim.

The current vaccine portfolio to be acquired has experienced revenue growth over the past three years, and Lilly expects the acquisition to be accretive to GAAP earnings in 2019 and to non-GAAP earnings in 2018.

John C. Lechleiter, Ph.D., Lilly’s chairman, president and chief executive officer, said that the planned acquisition of BIVI’s U.S. feline, canine and rabies vaccines portfolio reaffirms Lilly’s confidence in Elanco’s growth potential.

“As a result of the acquisition, Elanco will bring greater value to customers by providing a suite of options for preventing common diseases in companion animals,” said Lechleiter. “Coupled with our robust food animal portfolio, this addition further strengthens Elanco’s position in the global animal health business.”

Jefferies LLC is acting as the exclusive financial advisor and Paul Hastings LLP and Paul, Weiss, Rifkind, Wharton & Garrison LLP are acting as legal advisors to Elanco and Lilly in this transaction.

Categories: M&A, Strategy


You Might Also Like
Read Full PostRead - Eye Icon
M&A – Ensuring Success After the First 90 Days
Finance
11/05/2018M&A – Ensuring Success After the First 90 Days

Angelica Carr, Founder of Aim Business Coaching, explores how companies can ensure a smooth and swift transition during M&A deals.

Read Full PostRead - Eye Icon
Strong Increase of Equity Trading Volumes ( 17.4%) in 2014
Finance
04/03/2015Strong Increase of Equity Trading Volumes ( 17.4%) in 2014

The World Federation of Exchanges Ltd. released its Annual Statistics Market Highlights report.

Read Full PostRead - Eye Icon
Shining The Light On A Medical Marvel
Innovation
18/12/2019Shining The Light On A Medical Marvel

The fight against cancer has become one of the greatest in modern medical history, and scientific research continues to yield new medical methods for combating this disease. At the forefront of developing innovative technologies is Advanced Oncotherapy, a UK-b

Read Full PostRead - Eye Icon
Five Types of Security Your Business Office or Warehouse Needs Today
News
01/06/2022Five Types of Security Your Business Office or Warehouse Needs Today

Increasingly, safety in the workplace has become a priority for many business owners.  Ensuring workers are safeguarded from on-the-job hazards is simply a good practice to have in place.  It can protect your business from litigious consequences and helps yo

Read Full PostRead - Eye Icon
Pang & Co: Insight, Expertise, Dedication.
Finance
23/04/2015Pang & Co: Insight, Expertise, Dedication.

Based in Hong Kong, Pang & Co. focuses on capital market transactions and regulatory advice in Greater China, and IPOs in both the Main Board and the Growth Enterprise Market of the Stock Exchange of Hong Kong Limited.

Read Full PostRead - Eye Icon
CEO of the Month
Innovation
06/01/2016CEO of the Month

CTRL is a team of Information Technology experts dedicated to the optimization of their client’s business processes.

Read Full PostRead - Eye Icon
37% of businesses say apprentices will be top source of talent
Innovation
12/02/201837% of businesses say apprentices will be top source of talent

37% of businesses say apprentices will be top source of talent in 2018, survey finds

Read Full PostRead - Eye Icon
An Unwavering Commitment to Excellence
Finance
02/06/2017An Unwavering Commitment to Excellence

Bonassa Bucker Advogados has been involved in the implementation of several international enterprises, constituting companies and partnerships, as well as serving foreign investors from various sources. In this article, Fátima Cristina Bonassa Bucker provides

Read Full PostRead - Eye Icon
Bermuda: Poised for Economic Recovery
Finance
07/10/2015Bermuda: Poised for Economic Recovery

Oyster Consulting provides comprehensive and cost-effective compliance and operational consulting to the financial services industry.



Our Trusted Brands

Acquisition International is a flagship brand of AI Global Media. AI Global Media is a B2B enterprise and are committed to creating engaging content allowing businesses to market their services to a larger global audience. We have a number of unique brands, each of which serves a specific industry or region. Each brand covers the latest news in its sector and publishes a digital magazine and newsletter which is read by a global audience.

Arrow